Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22477364 | 0.81 | — | — | |
| SCHEMBL20094491 | 0.77 | GAA (0.31) | GAA | |
| SCHEMBL20365082 | 0.67 | MEN1 (0.31) | MEN1KMT2AALDH1A1LMNATP53 | |
| SCHEMBL12302971 | 0.66 | NPSR1 (0.34) | NPSR1 | |
| SCHEMBL5864436 | 0.64 | POLB (0.34) | — | |
| SCHEMBL9582378 | 0.60 | — | — | |
| SCHEMBL1333560 | 0.60 | — | — | |
| SCHEMBL1439655 | 0.60 | — | — | |
| SCHEMBL20094489 | 0.60 | ALOX15 (0.33) | ALDH1A1 | |
| SCHEMBL5864431 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111433181-B | Synthesis of bicyclo [2.2.2] octane derivatives | 伊士曼化工公司 | 2023-08-04 | — | — | CN | disclosed |
| US-11518726-B2 | Synthesis of bicyclo[2.2.2]octane derivatives | EASTMAN CHEMICAL COMPANY (US) | 2022-12-06 | — | — | US | disclosed |
| US-11518726-B2 | Synthesis of bicyclo[2.2.2]octane derivatives | EASTMAN CHEMICAL COMPANY (US) | 2022-12-06 | — | — | US | disclosed |
| US-20200270191-A1 | SYNTHESIS OF BICYCLO[2.2.2]OCTANE DERIVATIVES | EASTMAN CHEMICAL COMPANY (US) | 2020-08-27 | — | — | US | disclosed |
| US-10633315-B2 | Synthesis of bicyclo[2.2.2]octanes | EASTMAN CHEMICAL COMPANY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200039906-A1 | SYNTHESIS OF BICYCLO[2.2.2]OCTANES | EASTMAN CHEMICAL COMPANY (US) | 2020-02-06 | — | — | US | disclosed |
| WO-2019075004-A1 | SYNTHESIS OF BICYCLO[2.2.2]OCTANE DERIVATIVES | EASTMAN CHEMICAL COMPANY (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2018075301-A1 | SYNTHESIS OF BICYCLO(2.2.2)OCTANES | EASTMAN CHEMICAL COMPANY (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039906-A1 | SYNTHESIS OF BICYCLO[2.2.2]OCTANES | PPOX, ODC1, AOC2 | CYP19A1 317/4885GAA 4340/4885MEN1 3235/4885 |
| US-10633315-B2 | Synthesis of bicyclo[2.2.2]octanes | PPOX, ODC1, AOC2 | CYP19A1 317/4885GAA 4340/4885MEN1 3235/4885 |
| US-20200270191-A1 | SYNTHESIS OF BICYCLO[2.2.2]OCTANE DERIVATIVES | SCO2, AOC2, ODC1 | CYP19A1 298/4885GAA 3689/4885MEN1 3966/4885 |
| US-11518726-B2 | Synthesis of bicyclo[2.2.2]octane derivatives | SCO2, AOC2, ODC1 | CYP19A1 298/4885GAA 3689/4885MEN1 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.